Yader Sandoval1, Stephen W Smith2, Anne Sexter3, Sarah E Thordsen1, Charles A Bruen4, Michelle D Carlson1, Kenneth W Dodd4, Brian E Driver5, Yan Hu3, Katherine Jacoby4, Benjamin K Johnson1, Sara A Love6, Johanna C Moore5, Karen Schulz3, Nathaniel L Scott4, Fred S Apple7. 1. Division of Cardiology, Hennepin County Medical Center and Minneapolis Heart Institute, Abbott Northwestern Hospital, Minn. 2. Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, Minn; Department of Emergency Medicine, University of Minnesota, Minneapolis. 3. Minneapolis Medical Research Foundation, Minn. 4. Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, Minn; Department of Medicine, Hennepin County Medical Center, Minneapolis, Minn. 5. Department of Emergency Medicine, Hennepin County Medical Center, Minneapolis, Minn. 6. Minneapolis Medical Research Foundation, Minn; Department of Laboratory Medicine and Pathology, Hennepin County Medical Center and University of Minnesota, Minneapolis. 7. Minneapolis Medical Research Foundation, Minn; Department of Laboratory Medicine and Pathology, Hennepin County Medical Center and University of Minnesota, Minneapolis. Electronic address: apple004@umn.edu.
Abstract
BACKGROUND: Studies addressing patients with type 2 myocardial infarction and myocardial injury, including the impact of using high-sensitivity (hs) cardiac troponin (cTn) assays on their incidence are needed. METHODS: Ours is a prospective, observational US cohort study. Consecutive emergency department patients with serial cTnI measurements were studied. Outcomes included 180-day mortality and major adverse cardiac events, including 2-year follow-up for those with myonecrosis. RESULTS: Among 1640 patients, using a contemporary cTnI assay, 30% (n = 497) had ≥1 cTnI >99th percentile, with 4.7% (n = 77), 8.5% (n = 140), and 17% (n = 280) classified as type 1 myocardial infarction, type 2 myocardial infarction, and myocardial injury, respectively. Compared with patients without myonecrosis, 180-day mortality was higher for type 2 myocardial infarction (4% vs 13%, P < .0001) (adjusted hazard ratio 2.7; 95% confidence interval, 1.6-4.8; P = .0005) and myocardial injury (4% vs 11%, P < .0001) (adjusted hazard ratio 1.8; 95% confidence interval, 1.1-3.0; P = .02), both with mortality >20% at 2 years. Predictors of 2-year mortality for type 2 myocardial infarction included age, congestive heart failure, and beta-blockers. Relative to the contemporary cTnI assay, hs-cTnI had less myonecrosis (30% vs 26%, P = .003) and acute myocardial infarction (13.2% vs 10.8%, P = .032), including fewer type 2 myocardial infarctions (8.5% vs 6.3, P = .01), with no difference in myocardial injury (17% vs 15%, P = .1). CONCLUSIONS: cTnI increases are encountered in approximately a third of patients, the majority due to nonatherothrombotic conditions. Compared with patients without myonecrosis, type 2 myocardial infarction and myocardial injury have worse short-term outcomes, with mortality rates >20% at 2 years. hs-cTnI assay does not lead to more myocardial injury or infarction.
BACKGROUND: Studies addressing patients with type 2 myocardial infarction and myocardial injury, including the impact of using high-sensitivity (hs) cardiac troponin (cTn) assays on their incidence are needed. METHODS: Ours is a prospective, observational US cohort study. Consecutive emergency department patients with serial cTnI measurements were studied. Outcomes included 180-day mortality and major adverse cardiac events, including 2-year follow-up for those with myonecrosis. RESULTS: Among 1640 patients, using a contemporary cTnI assay, 30% (n = 497) had ≥1 cTnI >99th percentile, with 4.7% (n = 77), 8.5% (n = 140), and 17% (n = 280) classified as type 1 myocardial infarction, type 2 myocardial infarction, and myocardial injury, respectively. Compared with patients without myonecrosis, 180-day mortality was higher for type 2 myocardial infarction (4% vs 13%, P < .0001) (adjusted hazard ratio 2.7; 95% confidence interval, 1.6-4.8; P = .0005) and myocardial injury (4% vs 11%, P < .0001) (adjusted hazard ratio 1.8; 95% confidence interval, 1.1-3.0; P = .02), both with mortality >20% at 2 years. Predictors of 2-year mortality for type 2 myocardial infarction included age, congestive heart failure, and beta-blockers. Relative to the contemporary cTnI assay, hs-cTnI had less myonecrosis (30% vs 26%, P = .003) and acute myocardial infarction (13.2% vs 10.8%, P = .032), including fewer type 2 myocardial infarctions (8.5% vs 6.3, P = .01), with no difference in myocardial injury (17% vs 15%, P = .1). CONCLUSIONS:cTnI increases are encountered in approximately a third of patients, the majority due to nonatherothrombotic conditions. Compared with patients without myonecrosis, type 2 myocardial infarction and myocardial injury have worse short-term outcomes, with mortality rates >20% at 2 years. hs-cTnI assay does not lead to more myocardial injury or infarction.
Authors: Kris G Vargas; Paul M Haller; Bernhard Jäger; Maximilian Tscharre; Ronald K Binder; Christian Mueller; Bertil Lindahl; Kurt Huber Journal: Clin Res Cardiol Date: 2018-12-07 Impact factor: 5.460
Authors: Cian McCarthy; Sean Murphy; Joshua A Cohen; Saad Rehman; Maeve Jones-O'Connor; David S Olshan; Avinainder Singh; Muthiah Vaduganathan; James L Januzzi; Jason H Wasfy Journal: JAMA Cardiol Date: 2019-05-01 Impact factor: 14.676
Authors: Xiongyi Han; Myung Ho Jeong; Liyan Bai; Joon Ho Ahn; Dae Young Hyun; Kyung Hoon Cho; Min Chul Kim; Doo Sun Sim; Young Joon Hong; Ju Han Kim; Youngkeun Ahn Journal: Cardiovasc Diagn Ther Date: 2022-02
Authors: Claire E Raphael; Véronique L Roger; Yader Sandoval; Mandeep Singh; Malcolm Bell; Amir Lerman; Charanjit S Rihal; Bernard J Gersh; Bradley Lewis; Ryan J Lennon; Allan S Jaffe; Rajiv Gulati Journal: Circulation Date: 2020-01-06 Impact factor: 29.690
Authors: Andrew R Chapman; Philip D Adamson; Anoop S V Shah; Atul Anand; Fiona E Strachan; Amy V Ferry; Kuan Ken Lee; Colin Berry; Iain Findlay; Anne Cruikshank; Alan Reid; Alasdair Gray; Paul O Collinson; Fred Apple; David A McAllister; Donogh Maguire; Keith A A Fox; Catalina A Vallejos; Catriona Keerie; Christopher J Weir; David E Newby; Nicholas L Mills Journal: Circulation Date: 2019-10-07 Impact factor: 29.690
Authors: John Hung; Andreas Roos; Erik Kadesjö; David A McAllister; Dorien M Kimenai; Anoop S V Shah; Atul Anand; Fiona E Strachan; Keith A A Fox; Nicholas L Mills; Andrew R Chapman; Martin J Holzmann Journal: Eur Heart J Date: 2021-07-08 Impact factor: 35.855